37,784 Shares in Guardant Health, Inc. $GH Purchased by Hamilton Wealth LLC

Hamilton Wealth LLC bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, Holdings Channel reports. The fund bought 37,784 shares of the company’s stock, valued at approximately $3,859,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Erste Asset Management GmbH increased its stake in Guardant Health by 10.4% during the third quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock worth $43,716,000 after acquiring an additional 66,617 shares during the last quarter. Segall Bryant & Hamill LLC lifted its stake in shares of Guardant Health by 57.8% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after purchasing an additional 111,822 shares during the last quarter. World Investment Advisors purchased a new position in shares of Guardant Health during the 4th quarter worth $1,664,000. TD Asset Management Inc grew its holdings in shares of Guardant Health by 16.1% during the 3rd quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock worth $11,797,000 after purchasing an additional 26,210 shares during the period. Finally, GSA Capital Partners LLP increased its position in shares of Guardant Health by 155.5% during the 3rd quarter. GSA Capital Partners LLP now owns 21,982 shares of the company’s stock worth $1,373,000 after purchasing an additional 13,378 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Michael Brian Bell sold 2,000 shares of Guardant Health stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $128.62, for a total value of $257,240.00. Following the completion of the transaction, the chief financial officer owned 47,509 shares in the company, valued at approximately $6,110,607.58. This trade represents a 4.04% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Medina Manuel Hidalgo sold 1,000 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $130.06, for a total value of $130,060.00. Following the transaction, the director directly owned 639 shares of the company’s stock, valued at approximately $83,108.34. This represents a 61.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 449,006 shares of company stock worth $51,148,938 over the last ninety days. Company insiders own 5.60% of the company’s stock.

Guardant Health Trading Up 2.1%

NASDAQ:GH opened at $131.78 on Friday. The firm has a market cap of $17.47 billion, a PE ratio of -38.87 and a beta of 1.61. The stock has a fifty day moving average price of $106.46 and a 200 day moving average price of $102.68. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $135.00.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GH. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. Wolfe Research initiated coverage on shares of Guardant Health in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 price objective on the stock. Evercore raised shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price objective for the company in a research report on Tuesday, June 2nd. Wells Fargo & Company boosted their target price on Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. Finally, JPMorgan Chase & Co. lifted their price objective on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $141.95.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.